Advancing Dermatology

Meet the Target RWE dermatology team at AAD to explore how next-generation longitudinal evidence is shaping real-world strategy

Turning Real-World Dermatology Data Into Strategic Insight

As dermatology therapies enter the real world, access dynamics, treatment exposure, and patient experience often shape outcomes in ways clinical trials cannot fully predict. At AAD 2026, Target RWE is exploring how longitudinal real-world data, spanning retrospective and prospective patient journeys, can help organizations better understand these dynamics and generate the evidence needed to support medical, regulatory, and commercial decision making.

Connect With Our Team at AAD

Schedule a Time

Connecting Clinical Detail, Patient Experience, and Phenotype

Our Real-world dermatology patient cohorts support both deep retrospective characterization of care patterns and prospective evaluation of treatment pathways and outcomes.

Up to 3 years retrospectively and 5 years prospectively, from date of enrollment, with ongoing follow-up enabled through consent.

Includes disease activity scores, treatment sequencing, procedures, labs, imaging, and detailed medication history.

Link clinical signals with quality-of-life and biological measures.

Includes atopic dermatitis, alopecia areata, hidradenitis suppurativa —across academic and community practices

Our Research and Activity at AAD 2026

Target RWE researchers will present four studies leveraging real-world dermatology cohorts, demonstrating depth and breadth of longitudinal RWE:

  • 73571 – The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM

  • 75471 – A comparison of stable vs. progressive hidradenitis suppurativa: Insights from TARGET-DERM

  • 73553 – Machine Learning–Based Identification of Moderate-to-Severe Atopic Dermatitis in US Patients Using the TARGET-DERM Atopic Dermatitis Registry

  • 73555 – Real-world characteristics and burden of patients initiating advanced systemic therapy in the TARGET-DERM Atopic Dermatitis registry

Featured in the Journal of Drugs in Dermatology

Findings from “Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States” highlight how advanced therapy exposure varies across patient groups even after adjusting for clinical and demographic factors.

Contextualize real world outcomes when exposure is structurally mediated.

Design analyses that model treatment selection as it occurs in practice.

Interpret treatment variation using both clinical severity and access context.

Read the Article

Collaborate with the Target RWE Dermatology Team

We support drug development teams in:

  • Strategic consultation on longitudinal real-world study design

  • Evidence planning tied to clinical and regulatory objectives

  • Integration of retrospective + prospective data for robust real-world insights

  • Partnership on value demonstration for payers, regulators, and clinicians

Meet With Our Team at AAD

For detailed information on our solutions, please contact our team.

Schedule a Meeting